Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and <scp>drug–drug</scp> interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine-Reference-Cited by-同舟云学术

Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine

Published:2022-10-03 Issue:11 Volume:11 Page:1430-1442
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacom & Syst Pharma

Author:

Ngo Lien Thi¹^ORCID,Yang Sung‐yoon¹,Shin Sooyoung²^ORCID,Cao Duc Tuan³^ORCID,Van Nguyen Hung⁴^ORCID,Jung Sangkeun⁵,Lee Jae‐Young⁵,Lee Jong‐Hwa⁶⁷,Yun Hwi‐yeol¹^ORCID,Chae Jung‐woo¹^ORCID

Affiliation:

1. College of Pharmacy Chungnam National University Daejeon Korea

2. College of Pharmacy Ajou University Suwon Korea

3. Department of Pharmaceutical Chemistry and Quality Control Faculty of Pharmacy, Haiphong University Medicine and Pharmacy Haiphong Vietnam

4. Department of Pharmacology, Faculty of Pharmacy Haiphong University Medicine and Pharmacy Haiphong Vietnam

5. Department of Computer Science and Engineering Chungnam National University Daejeon Korea

6. Korea Institute of Toxicology Daejeon Korea

7. Department of Human and Environment Toxicology University of Science and Technology Daejeon Korea

Funder

Korea Environmental Industry and Technology Institute

National Research Foundation of Korea

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12844

Reference42 articles.

1. Bayer Pharma AGXarelto (rivaroxaban) Summary of Product Characteristics;2013.https://www.ema.europa.eu/en/documents/product‐information/xarelto‐epar‐product‐information_en.pdf

2. European Medicines Agency.CHMP assessment report for Xarelto;2008.https://www.ema.europa.eu/en/documents/assessment‐report/xarelto‐epar‐public‐assessment‐report_en.pdf

3. Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

4. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

5. In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimization of wet granulation process for manufacturing Rivaroxban generic immediate-release tablets using PBPK modeling and simulations;In Silico Pharmacology;2024-08-22

2. Applying Physiologically Based Pharmacokinetic Modeling to Interpret Carbamazepine’s Nonlinear Pharmacokinetics and Its Induction Potential on Cytochrome P450 3A4 and Cytochrome P450 2C9 Enzymes;Pharmaceutics;2024-05-30

3. Application of the Population Pharmacokinetics Model-Based Approach to the Prediction of Drug–Drug Interaction between Rivaroxaban and Carbamazepine in Humans;Pharmaceuticals;2023-05-02